Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Sjogren's Syndrome, Oral Health
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes
Interventions: FCL+BPS, FCL; Device
Lead sponsor: Marc Breton; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Epithelial Ovarian Cancer
Interventions: Pembrolizumab, E7777; Drug
Lead sponsor: Alexander B Olawaiye, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hematuria, Urothelial Carcinoma
Interventions: Cxbladder; Diagnostic Test
Lead sponsor: Pacific Edge Limited; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: San Diego, California • Bay Pines, Florida • Miami, Florida + 7 more

Conditions: Cervical Cancer
Interventions: carboplatin, cisplatin, paclitaxel, intensity-modulated radiation therapy, standard external beam radiation therapy, Optional brachytherapy boost; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 119
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 98 more

Conditions: B-Cell Acute Lymphoblastic Leukemia
Interventions: CTL019; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 25 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 25 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 12 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 48
States / cities: Downey, California • Long Beach, California • Los Angeles, California + 28 more

Conditions: Cognitive Function Assessment, Mental Fatigue
Interventions: Creatine Monohydrate, Maltodextrin Placebo; Dietary Supplement
Lead sponsor: University of Northern Iowa; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Cedar Falls, Iowa

Conditions: Multiple Sclerosis
Interventions: Alemtuzumab, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Seah Lim M.D.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Amarillo, Texas

Conditions: Bronchiolitis
Interventions: Winix 5500-2 HEPA filtration units; Other
Lead sponsor: IDeA States Pediatric Clinical Trials Network; Network
Eligibility: 1 Week to 12 Months
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 17
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Honolulu, Hawaii + 14 more

Conditions: Sanfilippo Syndrome, MPS3
Interventions: Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day; Drug
Lead sponsor: Ozlem Goker-Alpan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Non-Hodgkin's Lymphoma
Interventions: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Ifosfamide, Carboplatin, Etoposide, High-dose cyclophosphamide, PET scan; Biological · Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Aging, Disease
Interventions: High Intensity Interval training; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 65 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
Interventions: ranibizumab 0.5mg, ranibizumab 1.0mg; Drug
Lead sponsor: Hanscom, Thomas, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321); Drug
Lead sponsor: Bayer; Industry
Eligibility: 50 Years and older
Enrollment: 1,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 57
States / cities: Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more

Conditions: High Cholesterol, High Blood Pressure, Colorectal Cancer, Breast Cancer, Prostate Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 75 Years
Enrollment: 539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions: Azacitidine, MGCD0103; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
Interventions: Encorafenib, Binimetinib, Research Bloods, Tumor Tissue; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Birmingham, Alabama • Baltimore, Maryland • Winston-Salem, North Carolina

Conditions: Underage Drinking
Interventions: eCHECKUP TO GO; Behavioral
Lead sponsor: Boise State University; Other
Eligibility: 16 Years to 18 Years
Enrollment: 311 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Anal Cancer
Interventions: HspE7; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Brain Tumor, Cervical Cancer
Interventions: 18F-FTX; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sleep Apnea, Obstructive, Delirium
Interventions: CPAP; Device
Lead sponsor: Duke University; Other
Eligibility: 50 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: High Risk MDS
Interventions: Azacitidine, Azacitidine plus Deferasirox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Little Rock, Arkansas • Duarte, California • Baltimore, Maryland + 3 more

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: AMV564 14-Day CIV; Drug
Lead sponsor: Amphivena Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Duarte, California • Tampa, Florida • St Louis, Missouri + 2 more

Search by objective public record fields.

Oral Health Needs Assessment of Sjogren s Syndrome and Salivary Gland Dysfunction Cohorts and Healthy Volunteers Evaluating Oral Health Disparities as Determinants of Oral Health in a High-Risk Population

Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed Loop Insulin Delivery

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

Efficacy and Utility of Cxbladder Tests in Hematuria Patients

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

The Safety of Different Dose Levels of Zidovudine in HIV-Infected Children

Effects of Short-Term Creatine Supplementation on Cognitive Function in Healthy Young Adults

High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment

Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters

An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Interval Training, Inflammation and Immune Function

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

Efficacy of a Web-Based Alcohol Intervention for High School Students

SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia

Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR

Effect of CPAP on Postoperative Delirium

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes